Can 3D breast imaging spot more dangerous cancers than standard mammograms?

NCT ID NCT04461808

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether tomosynthesis (a 3D X-ray technique) combined with synthetic 2D images can reduce the number of advanced and interval breast cancers compared to standard digital mammography. Over 10,000 women scheduled for routine screening will be randomly assigned to one of the two methods. The goal is to see if the newer technology catches more aggressive tumors early, when they are easier to treat.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tomosynthesis plus synthetic 2D mammography
What this could lead to
If tomosynthesis proves better at catching aggressive cancers early, it could become a new standard for breast cancer screening, potentially reducing deaths.
What could go wrong
This is a single-round screening comparison, so long-term benefits are not yet known. Tomosynthesis may also increase false alarms or overdiagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Integrata

    Verona, Italy

  • Azienda Ulss 9 Scaligera

    Verona, Italy

  • Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia

    Reggio Emilia, Italy, 42122, Italy

  • IRCCS Policlinico San Donato

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.